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ABSTRACT 
Cisplatin analogs, having cytotoxic activity higher than that exerted by cisplatin, have recently triggered considerable interest by the 
community. The cis-[PtCl2(DMSO)HL]·2DMSO, where HL = 7-amino-2-(methylthio)[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic 
acid, has shown a potent cytotoxic activity on HepG2 hepatocarcinoma cells, while under identical conditions, it did not affect normal 
immortalized human liver cells (Chang). In this work, the above complex has been incorporated into MCM41 mesoporous silica, pure 
and functionalized with amino group, which is considered one of the best host for a drug delivery system for carrying high dosages of a 
variety of drugs in their mesopores. Since the controlled release of an anticancer drug helps to maintain its therapeutic level for an 
extended time period while minimizing undesirable high peaks immediately following administration, the in vitro tests have been 
performed in order to obtain the corresponding drug release profile. The investigated system demonstrated to be an efficient system for 
pharmaceutic controlled release. A deepened characterization of the systems has been performed in order to known their structure and 
features and to speculate the mechanisms involved in the release.  
Keywords: MCM41, amino groups, Cisplatin analogs, XRD, 29Si {1H} CP-MAS NMR, controlled release. 
1. INTRODUCTION 
 Drug carriers play a critical role for the loading and the 
release of the drug. Promising frontiers is represented by a new 
class of innovative medicines based on directional transport 
vehicles "drug delivery" and consist of assembled structures 
carrier (nano)-drug.  
 Silica-based materials, nontoxic, biocompatible, have been 
used as adjuvant and excipient in pharmaceutical technology. 
Within this class of compounds, mesoporous silica materials such 
as MCM41, SBA-15 and HMS have been investigated for 
medication and drug delivery due to their properties. The large 
surface area and pore volume, together with the nanoporous 
structure facilitate the control release of drugs. Many papers report 
the incorporation and the release of drugs and vitamins from 
MCM41 framework [1-5]. The resulting materials exhibit unique 
physicochemical properties determined by the state of the guest 
molecules, in addition to the nature of the mesoporous and its 
features (structure and pore size) and to the functional groups on 
the surface [6,7]. In fact, the functionalization with several kinds 
of molecules of the porous internal surface can influence the 
physical - chemical interactions between the mesoporous and the 
drug, thus controlling the delivery in terms of kinetics. In 
particular, the synthetic drug delivery systems have great potential 
to overcome the problems associated with systemic toxicity of 
chemotherapy, including treatment with platinum-based drugs [8]. 
For these reasons, some authors have reported the incorporation of 
the cisplatin in mesoporous compounds investigating the 
controlled release in vitro at human condition [9-14]. In the 
meantime, the discovery of successful candidates and strategies 
for the selective directionality of platinum drugs is a very active 
area of research. Novel platinum(II) complexes including 
nanotechnology applications and complexes containing 
heterocyclic ligands with N and S donor atoms are under study 
with the aim to reduce and overcome the toxicity of cisplatin and 
its analogues, and to decrease the nephrotoxicity of platinum 
complexes [15].  
 Recently, a new anticancer drug, the cis-
[PtCl2(DMSO)HL]·2DMSO, where HL = 7-amino-2-
(methylthio)[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid, 
hereafter called complex (1), has been synthesized and tested by 
some of us [15]. The class of compounds of triazolopyrimidine 
shows antimicrobial and antitumor properties and can be used to 
study metal-ligand interaction in biological systems. The complex 
(1) exhibited a very marked biological activity on HepG2 
hepatocarcinoma cells while under identical conditions it did not 
affect normal immortalized human liver cells (Chang Liver cells). 
The mechanism of anti-proliferative effect of the complex (1) on 
HepG2 was pro-apoptotic and the antiproliferative efficacy was 
twofold higher than that shown by cisplatin. 
 In this work, due to the observed properties and the 
potential in the enhanced anticancer activity, the complex (1) has 
been incorporated in a mesoporous materials in order to obtain a 
controlled release system. Similar study on cisplatin analogues has 
not yet investigated to the best of our knowledge. Since many 
authors claim the importance of a proper support selection as a 
strategy to control the delivery of active molecules, making a 
correlation between textural properties and release kinetics, the 
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mesoporous silica MCM41 and the mesoporous silica MCM41 
functionalized with amino groups (MCM41-NH2) have been used 
as host for this study. The role of the amino group in the 
encapsulation efficiency and in the release kinetics of the complex 
(1) has been thus investigated. 
 The characterization of the materials was performed by 
using X-ray Diffraction (XRD), Gas adsorption, 29Si Cross 
Polarization - Magic Angle Spinning NMR Spectroscopy (29Si 
{1H} CP MAS NMR). The loading capacity and the release of 
complex (1) in a phosphate buffer solution (PBS) at pH 7.4 and 
37°C in order to simulate the human conditions was evaluated by 
using the Uv-vis Spectroscopy.  
 
2. EXPERIMENTAL SECTION 
2.1. Materials. Tetraethoxysilane (TEOS, 99%, Fluka), 
cetyltrimetylammonium bromide (CTAB, 98%, Aldrich), 
ammonia solution (28%, Aldrich), ethanol (99.8%, Fluka), 3-
aminopropyl triethoxysilane (APTES 98%, Aldrich), anhydrous 
toluene (99.8%, Aldrich), diethyl ether (99.9%, Aldrich), 
dichloromethane (99.5%, Aldrich), chloroform (99.5%, Aldrich), 
phosphate buffer solution (PBS, 0.1M, pH=7.5, Aldrich), were 
used as received. Solutions were prepared by weight adding 
conductivity grade water. 
2.2. Samples preparation. The syntheses of the complex (1) 
and of the MCM41 mesoporous silica are reported elsewhere 
[15,16]. The MCM41-NH2 was prepared as follows. MCM41 
silica was dehydrate at 60°C for 2 h to remove physisorbed water. 
1 g of MCM41 was thus dispersed in 40 mL of anhydrous toluene 
and 1.2 mL of APTES, used as functionalizing agent, was added 
to the dispersion. The reaction was carried out at room 
temperature for 20 h and then refluxed for 4 h. The suspension 
was filtered and washed with a 1:1 mixture of diethyl ether and 
dichloromethane and dried at 60°C for 3 days.  
The complex (1) loading was performed by following the 
experimental procedure reported by Mori [14]: MCM41 and 
MCM41-NH2 samples were soaked, under continuous magnetic 
stirring for 24 h at room temperature, into a chloroform solution of 
complex (1) (0.06 mg/mL). The complex (1) to the mesoporous 
weight ratio was 1:4. The loaded samples were recovered by 
vacuum filtration, washed with chloroform and dried under 
vacuum overnight. The supernatant was collected and analysed 
using UV-vis spectroscopy to determine the unloaded amount of 
complex (1) and by difference the loaded quantity on the 
mesoporous. 
2.3. Instrumentation. UV–vis absorption spectra of solutions of 
complex (1) were recorded in the range 200–400 nm using a 
double beam Beckman DU-800 spectrophotometer with a 
resolution of 1.0 nm. In order to eliminate the effect of 
instrumental errors and of particle diffusion, the value of 
absorbance at 400 nm was subtracted to each spectrum. 
X-ray Diffraction (XRD) patterns were acquired by using a 
PW 1050 Philips diffractometer in the Bragg-Brentano geometry 
equipped with a Cu Coolidge tube and a scintillation detector 
beam (40 kV, 30 mA, step 0.05° , counting time 5s/step). The 
instrument resolution (divergent and antiscatter slits of 0.5◦) was 
determined using standards free from the effect of reduced 
crystallite size and lattice defects.  
N2 absorption-desorption isotherms were registered at 77 K 
using a Quantachrome Nova 2200 Multi-Station High Speed Gas 
Sorption Analyser. Samples were outgassed for 3 hr at room 
temperature in the degas station. Adsorbed nitrogen volumes were 
normalized to the standard temperature and pressure.  
29Si {1H} CP–MAS NMR spectra were obtained at room 
temperature on a Bruker Avance II 400 MHz (9.4 T) spectrometer 
operating at 79.4 MHz. Samples were compressed in 4 mm 
zirconia rotors with Kel-F (PCTFE) caps. The 29Si spectra were 
acquired using a MAS rate of 5 kHz, 4096 scans, contact time of 8 
ms, an excitation pulse on the 1H nucleus of 4.15 µs and repetition 
delay of 8 s. The contact time values were optimized on the 
samples through variable contact time (VCT) experiments and the 
optimization of the Hartmann–Hahn condition [17] was obtained 
by means of a Q8M8 (Si[(CH3)3]8Si8O20) standard. 
2.4. Study of complex (1) release. In vitro drug release was 
evaluated at 37±1 °C in 0.1 M phosphate buffer solution (PBS) 
having pH 7.4 to simulate the physiological pH of blood. 40 mg of 
complex (1) loaded samples were placed with 2 mL of PBS in a 
closed 3,5 kDa dialysis membrane tube (Spectra/Por 3 Dialysis 
membrane. 3,5 MWCO, 11,5 mm diameter), and then in a 
Nalgene-flask filled with PBS. The total amount of PBS was 20 
mL. The flask was closed and kept under shaking (60 rpm) at 
37±1 °C. At scheduled time intervals, an aliquot of the solution 
was taken and the UV-Vis spectrum was recorded.  
 
3. RESULTS SECTION 
3.1. Determination of the complex (1) amount loaded on the 
mesoporous materials. For calibration purposes, five standard 
solutions of complex (1) were prepared in chloroform in the range 
of 0.01-0.08 mg/mL. The UV-vis spectra of the standard solutions 
are reported in Figure S1 of the Support Information (S.I.). The 
calibration curve, obtained by plotting the absorbance values of 
the band maximum (λmax = 300 nm) versus the standard solution 
concentrations, is reported in Figure S2 of the S.I.. 
The complex (1) encapsulation efficiency % (EE%) of 
MCM41 and MCM41-NH2 samples were evaluated using the 
following method: the filtrate was collected and analysed using 
UV-vis spectroscopy.  
From the absorbance values of the band maximum, the 
amount of unloaded complex (1) was derived. The loaded 
complex (1) amount was calculated as difference between the 
stoichiometric quantity and the complex (1) unloaded.  
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The EE% was 75.0 w/w % and 83.3 w/w % for the MCM41 
and the MCM41-NH2 samples, respectively (all loading 
measurements were performed in triplicate). The higher value 
obtained for the functionalized system is an indication that some 
specific interactions between the amino group and the complex (1) 
may be established.  
On the other hand, the obtained high value for the MCM41 
is an indication that electrostatic and dipolar interactions, favored 
by the solvent, may have a role in the loading, thus suggesting that 
functionalization is not the major factor boosting drug uptake. 
3.2. Structural investigation. The XRD patterns of MCM41 and 
of MCM41-NH2 samples are reported in Figure 1.  
 
 
Figure 1. XRD patterns of MCM41 and of MCM41-NH2 samples. 
 
The XRD pattern of MCM41 is characteristic of the 
hexagonal structure: a peak of high-intensity (100) and three 
reflections of low-intensity (110, 200 and 210) [16,18,19]. No 
reflection was observed in the high angle region of XRD patterns 
for both samples. 
The mesoporous structure is basically preserved after the 
functionalization (MCM41-NH2 sample) even if, comparing the 
two XRD patterns, a shift and a decrease of the (100) peak 
together with the disappearing of the secondary peaks is observed. 
The adjacent pores centre-centre distance, a0, of all samples was 
calculated by means of the equation α0 = 
     
√ 
 [20], where d100 is 
the d100 spacing computed by using the Bragg’s law. For each 
sample, the calculated a0 values are reported in the Table 1.  
 
Table 1. Structural data of samples (a0, lattice parameter; SBET, specific 
surface area; wBJH, pore width; Vt, total pore volume). 
Sample α0 (Å) 
SBET  
(m2g-1)* 
wBJH 
(Å) 
Vt 
(cc/g) 
MCM41 41(1) 1276 35 1.35 
MCM41/complex (1) 39(1) 393 33 0.47 
MCM41-NH2 38(1) 87 37 0.07 
MCM41-NH2/complex (1) 38(1) 23 37 0.02 
* The uncertainty on the SBET values is 5%. 
 
 The decrease of α0 as a consequence of the functionalisation 
can be ascribed to the formation of hydrogens bonds among the 
amino groups that promote a shrinking of the porous structure 
[13]. The XRD patterns of the complex (1) loaded samples are 
reported in Figure 2.  
 For comparison the XRD pattern of MCM41 and of 
MCM41-NH2 samples are reported in the same figures. In general, 
the XRD patterns showed, for both loaded samples, that the 
hexagonal lattice symmetry is maintained after the loading 
indicating that the porous structure of the MCM41 is maintained 
as a consequence of the loading.  
 The XRD patterns of the loaded samples show a decrease in 
intensity of the (100) peak respect to that of the unloaded one as a 
consequence of a variation in the electron density. For both loaded 
samples, the α0 value is 39(1) Å. It does not significantly change 
with respect to the unloaded samples. Detailed analysis of these 
small changes is outside the scope of this work. Similar results are 
reported in literature [21] where several factor such interactions 
between molecules and changes in overall background scattering 
of X-rays are taken into account. 
 
 
Figure 2. XRD patterns of A) MCM41 and of MCM41/complex (1) and 
of B) MCM41-NH2 and of MCM41-NH2 /complex (1) samples. 
 
 Since the pore diameter is 41 (1) and 38 (1) Å respectively 
for MCM41 and for MCM41-NH2 and the size of complex (1) 
molecule is ca. 9 Å, diffusion of the drug is unlikely to be the 
limiting factor for complex (1) uptake. Hence, the differences 
found in the amount of drug loaded are likely to reflect 
corresponding differences of interaction energy between the drug 
molecule and the pore wall, which are expected to depend on the 
functional group. 
Nitrogen adsorption-desorption isotherms were registered 
to obtain information about the specific surface area (SBET) and the 
total pore volume (Vt). Some of them are reported in Figure S3 of 
the S.I.. According to IUPAC [22] the characteristic type IV-
isotherms is obtained for the MCM41.  
Once functionalized, the obtained isotherm of the MCM41-
NH2 is of type I. Similar results have been reported by Zeng at al 
[23] who hypothesize the presence of secondary interparticle 
mesopores, which are favorable for drug delivery applications. 
The same type of isotherm has been obtained as a consequence of 
the complex(1) uptake for both MCM41 and MCM41-NH2. 
The SBET was calculated by using the BET method [24] in 
the relative adsorption pressure (P/P0) range from 0.045 to 0.250. 
The Vt was obtained from the nitrogen amount adsorbed in 
correspondence of P/P0 equal to 0.99.  
SBET, and Vt, are reported in Table I. As expected, after the 
functionalisation the surface area and the pore volume of MCM41 
significantly decrease as well as after the loading. It is well known 
that the aminopropyl functional groups added with the used post-
synthesis procedure tend to distribute near the entrance of the 
mesoporous channels, thus explaining the observed high decrease 
of surface area [25].  
The findings also evidence the presence of the drug within 
the pores. During the loading the chloroform solution containing 
the complex (1) diffuse into the pores. After the chloroform 
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removal and the drying process the molecules remain trapped 
partially obstructing the mesochannels, analogously to the ones 
reported by Zeng at al [25]. 
The 29Si 1H CP-MAS NMR spectra of MCM41, 
MCM41/complex (1), MCM41-NH2, MCM41-NH2/complex (1) 
samples are reported in Figure 3. 
 
 
Figure 3. 29Si 1H CP-MAS NMR spectra of MCM41, MCM41-NH2, 
MCM41/complex (1), and MCM41-NH2/complex (1) samples.  
 
The 29Si 1H CP-MAS NMR spectrum of MCM41 shows 
three broad, Q2, centred at around -90 ppm, due to the geminal 
silanols, , Q3, at around -100 ppm, due to the silicon atoms bearing 
one hydroxyl group and, Q4, at around -109 ppm, due to the 
silicon atoms without hydroxyl groups [16,18,19].  
In the 29Si 1H CP-MAS NMR spectrum of MCM41-NH2 
two new resonances (T2 and T3) corresponding to two different 
environments for the siloxane groups in the functionalized 
material are present [20]. The T3 at -66.7 ppm and the T2 at -58.7 
ppm are due to RSi(OSi)3 terminal units and to (SiO)2R-Si(OH) 
cross-linked units, respectively. The presence of T2 and T3 peaks 
evidences the covalent linkage between the aminopropyl groups 
and the silica surface. In addition, as the grafting reaction takes 
place, a marked increase of the Q4 peak intensity together with a 
decrease of the Q2 peak is observed. This indicates the conversion 
of the (SiO)3Si–OH species to fully condensed species occurred 
due to the grafting.  
Knowing that the samples show the same chemical shifts 
and the same cross polarization dynamic, and that the variation of 
the contact time does not modify the relative intensity distribution 
of the signals, the deconvolution of each spectrum has been 
performed to calculate the single contributions of the signal, as 
performed by some of us [16] for the quantification of the 
different silicon groups. The obtained values are reported in Table 
2. As reported by some authors, the relative integrated intensities 
of NMR signals of the organosiloxane (∑Tm) and siloxane (∑Qm) 
(T/Q ratio) can be employed to estimate the incorporation degree 
of functional groups [25]. The T/Q ratio for the MCM41-NH2 is 
0.63, implying high surface coverage of amino groups, which 
were available for incorporation processes of drug molecules. For 
the MCM41-NH2/complex(1) this value is 0.57, roughly 
coincident with the previous one in the limit of the experimental 
errors. This means that the silicon environment unchanged in the 
presence of the complex (1). However, looking for the area of 
single contributes, for the MCM41-NH2 /complex(1) sample, Q2 
increase of 91%, Q3 decrease of 4% and Q4 increase of 0.6%, T2 
increase of 68% and T3 decrease of 25%, respect to the values 
calculated for the MCM41-NH2. 
Notwithstanding, the opposite trend observed for the 
MCM41/complex(1), where Q2 decrease of 30%, Q3 increase of 
5% and Q4 increase of 2.7%, all these findings indicate that the 
complex (1) influence the dynamic of cross polarization and it is 
an indication that the drug is located inside the pore of the two 
mesoporous.  
 
Table 2. Peaks areas obtained by deconvolution of the 29Si {1H} CP-
MAS NMR area.  
 
106 
T2 
106 
T3 
106 
Q2 
106 
Q3 
106 
Q4 
T/Q 
ratio 
MCM41 - - 214.5 1057 332.1 - 
MCM41/complex 
(1) 
- - 154.3 1131 347.3 - 
MCM41-NH2 178.8 487. 24.1 452.2 574.9 0.63 
MCM41-
NH2/complex(1) 
378.6 460.7 64.0 604.4 797.1 0.57 
 
3.3. Study of the release. The drug release profile is of great 
importance in applying the synthesized systems to a practical drug 
delivery for cancer chemotherapy. For calibration purposes, five 
standard solutions of complex (1) in PBS were prepared in the 
range of 0.0025-0.015 mg/mL. The UV-vis spectra of the standard 
solutions are reported in Figure S5 of the S.I.. The calibration 
curve, obtained by plotting the absorbance values of the band 
maximum (λmax = 246 nm) versus the standard solution 
concentrations, is reported in Figure S6 of the S.I. 
In order to evaluate the amount of the complex (1) released 
in the PBS solution, the Uv-vis spectra were acquired at scheduled 
time intervals. The UV-vis spectrum of each aliquot taken by the 
MCM41-NH2/complex (1) and the MCM41/complex (1) systems 
is reported in Figure S7 and S8, respectively.  
The amount of released complex (1) was calculated by the 
maximum of the absorption band at 246 nm on the basis of the 
calibration curve. The release profile of the complex (1) from both 
loaded functionalized and non-functionalized samples was studied 
as a function of time and the results are reported in Figure 4.  
 
 
Figure 4. Release profile of complex (1) in PBS solution from the 
MCM41/complex (1) and MCM41-NH2/complex (1) samples.  
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As can be seen, the two systems exhibit different drug 
release profiles. In this sense, some aspects are worth to be 
considered. The in vitro release of complex (1) from MCM41 and 
MCM41-NH2 mesoporous has been performed for 96 hours. After 
2 hours the MCM41/complex (1) system reached maximum 
release ratio, while the MCM41-NH2/complex (1) release in 3 
hours. The maximum released complex (1) ratios are 48.3 % and 
63.8 % for pure and amino functionalized MCM41 loaded 
samples, respectively. MCM41 system reached the plateau 
concentration faster than MCM41-NH2 system. The functionalized 
MCM41 shows slow complex (1) release. Many authors explain 
the different release taking in account the interactions between the 
drug and the functional groups of the mesoporous. In this case, the 
different release rate may be due to the properties of the modified 
MCM-41. Respect to the MCM41, in the MCM41-NH2 the 
presence of the hydrocarbon chains confer the pore surface a 
rather hydrophobic character, hence a higher affinity for molecules 
of lower polarity, but at the same time the amino groups could 
interact by means of an hydrogen bonding interactions with the 
nitrogens of the amino groups or with the oxygens of the 
carboxylic groups of the complex (1). These interaction are 
responsible of the higher loading, having as medium the 
chloroform, in the mesoporous functionalised with amino groups.  
 
 
4. CONCLUSIONS 
 This work reports a promising suitably strategy for the 
controlled release of drugs like the cisplatin derivatives in 
therapeutic applications. The preparation and the characterization 
of two drug delivery systems, MCM41/complex (1) and MCM41-
NH2/complex (1), was reported. In both case, the maintenance of 
the hexagonal structure after the functionalization and the complex 
(1) loading was checked by XRD. Experimental results showed 
that ordered mesoporous structure is preserved after the 
functionalization and that the complex (1) does not affect the 
hexagonal structures. The surface area and the pore volume of the 
mesoporous decrease with the complex (1) loading indicating that 
the molecule is inside the pores. NMR investigation show that the 
different silicon environments are influenced by the drug in terms 
of magnetisation transfer, confirming that the drug is inside the 
pores.  
MCM41-NH2 showed a greater drug uptake than pure MCM41 
and, in addition, it is more effective than pure MCM41 as a carrier 
of controlled delivery of complex (1) releasing more than 63 % of 
complex (1) at first 24 hours. Probably, it is due to hydrogen 
bonding interaction between the amino groups on silica walls and 
some groups of complex (1). These studies clearly shows that the 
complex (1) can be efficiently released from the amino-
functionalized MCM41 mesoporous silica. The mesoporous 
materials have many advantages as drug delivery systems but 
there are many questions about their behaviors in vivo conditions 
such as pharmacokinetics, pharmacodynamics and toxicity etc.  
Supporting Information Available. UV spectra, Nitrogen 
adsorption-desorption isotherms and relative calibration curves.  
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